- Home
- LSH vs CANF Comparison
LSH vs CANF Comparison
Compare LSH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- CANF
- Stock Information
- Founded
- LSH 2018
- CANF 1994
- Country
- LSH United States
- CANF Israel
- Employees
- LSH N/A
- CANF N/A
- Industry
- LSH
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- LSH
- CANF Health Care
- Exchange
- LSH NYSE
- CANF Nasdaq
- Market Cap
- LSH 7.3M
- CANF 7.9M
- IPO Year
- LSH 2024
- CANF N/A
- Fundamental
- Price
- LSH $1.00
- CANF $1.17
- Analyst Decision
- LSH
- CANF Strong Buy
- Analyst Count
- LSH 0
- CANF 2
- Target Price
- LSH N/A
- CANF $14.00
- AVG Volume (30 Days)
- LSH 36.9K
- CANF 412.3K
- Earning Date
- LSH 05-01-2025
- CANF 05-06-2025
- Dividend Yield
- LSH N/A
- CANF N/A
- EPS Growth
- LSH N/A
- CANF N/A
- EPS
- LSH N/A
- CANF N/A
- Revenue
- LSH $16,927,719.00
- CANF $674,000.00
- Revenue This Year
- LSH N/A
- CANF $461.72
- Revenue Next Year
- LSH N/A
- CANF N/A
- P/E Ratio
- LSH N/A
- CANF N/A
- Revenue Growth
- LSH 2.84
- CANF N/A
- 52 Week Low
- LSH $0.88
- CANF $1.22
- 52 Week High
- LSH $5.37
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- CANF 37.12
- Support Level
- LSH N/A
- CANF $1.14
- Resistance Level
- LSH N/A
- CANF $1.27
- Average True Range (ATR)
- LSH 0.00
- CANF 0.12
- MACD
- LSH 0.00
- CANF -0.02
- Stochastic Oscillator
- LSH 0.00
- CANF 4.46
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).